Our study establishes FCGR2A as a pivotal interface between metabolic inflammation and ccRCC progression, reconciling the paradoxical association of obesity with both increased cancer risk and enhanced immunotherapy responses (8). This evidence concerns the gene FCGR2A and cancer.